Steul Katrin, Schmehl Cleo, Berres Marlene, Hofmann Sabine, Klaus-Altschuck Andrea, Hogardt Michael, Kempf Volkhard Aj, Pohl Marcus, Heudorf Ursel
MRE-Netz Rhein-Main, Frankfurt am Main.
MEDIAN Kliniken Hessen GmbH & Co. KG, Bad Nauheim.
Rehabilitation (Stuttg). 2020 Dec;59(6):366-375. doi: 10.1055/a-1199-9083. Epub 2020 Aug 31.
After a first large-scale study on multi-drug resistant organisms (MDRO) in rehabilitation facilities in 2014, the Rhine-Main network on MDRO carried out another investigation in 2019. With regard to the recently published KRINKO recommendations on multidrug resistant enterococci, now vancomycin -resistant enterococci (VRE) and multi-drug resistant gram-negative pathogens (3MRGN and 4MRGN, i. e. gramnegative organisms resistant against 3 resp. 4 groups of antiinfectiva) were investigated.
A total of 16 hospitals took part, including one clinic for early neurological rehabilitation (ENR). Patient participation was voluntary. Rectal swabs were analyzed in a medical-microbiological laboratory (certified according to DIN ISO 15189) using standard methods (including MALDI-TOF-MS and VITEK 2 resistance testing according to EUCAST). By using the standardized questionnaire of the Europe-wide HALT examination (healthcare associated infections in long-term care facilities), patient characteristics (age, gender, hospital, surgical and MDRO medical history, , current antibiotic therapy etc.) were collected.
928 patients took part in the study, 895 from general rehabilitation facilities (GR) and 33 from early neurological rehabilitation (ENR). 65% of GR patients (ENR 100%) had been hospitalized in the previous 6 months, 29% (ENR 100%) of the patients had been admitted directly from a hospital, 22% (ENR 64%) had received antibiotic therapy in the last 3 months. were rarely used in GR patients with 1% overall, but often in the ENR with 61% urinary catheters and 36% vascular catheters. 2.2% (ENR 33.3%) of GR patients were colonized with VRE and 6.7% (ENR 18.2%) with 3MRGN; one patient exhibited a 4MRGN (ENR 0).
Compared to our previous study, there were no significant changes in the patient characteristics. The VRE prevalence was low at 3.3%, the prevalence of 3MRGN was higher compared to 2014 (7.1% vs. 3.6%). Risk factors for VRE and 3MRGN colonization (significant increased odds ratio) were: history of hospital treatment and an increased need for care due to restricted mobility, incontinence and disorientation. In addition, previous antibiotic treatment and skin barrier injuries due to or wounds were detected as further risk factors for VRE colonization.
在2014年对康复机构中的多重耐药菌(MDRO)进行首次大规模研究之后,莱茵 - 美因MDRO网络于2019年开展了另一项调查。关于最近发布的关于多重耐药肠球菌的KRINKO建议,现在对耐万古霉素肠球菌(VRE)和多重耐药革兰氏阴性病原体(3MRGN和4MRGN,即对3种或4种抗感染药物耐药的革兰氏阴性菌)进行了调查。
共有16家医院参与,其中包括一家早期神经康复诊所(ENR)。患者参与是自愿的。直肠拭子在医学微生物实验室(根据DIN ISO 15189认证)使用标准方法(包括基质辅助激光解吸电离飞行时间质谱和根据欧洲药敏试验委员会标准的VITEK 2耐药性检测)进行分析。通过使用全欧洲HALT检查(长期护理机构中的医疗相关感染)的标准化问卷,收集患者特征(年龄、性别、医院、手术和MDRO病史、当前抗生素治疗等)。
928名患者参与了研究,895名来自普通康复机构(GR),33名来自早期神经康复(ENR)。65%的GR患者(ENR为100%)在过去6个月内住院,29%的患者(ENR为100%)直接从医院转入,22%的患者(ENR为64%)在过去3个月内接受过抗生素治疗。导尿管在GR患者中很少使用,总体使用率为1%,但在ENR中经常使用,使用率为61%,血管导管使用率为36%。2.2%的GR患者(ENR为33.3%)被VRE定植,6.7%的GR患者(ENR为18.2%)被3MRGN定植;一名患者检测出4MRGN(ENR为0)。
与我们之前的研究相比,患者特征没有显著变化。VRE患病率较低,为3.3%,3MRGN患病率与2014年相比有所升高(7.1%对3.6%)。VRE和3MRGN定植的危险因素(优势比显著增加)为:住院治疗史以及因行动不便、失禁和定向障碍导致护理需求增加。此外,先前的抗生素治疗以及因[未明确内容]或伤口导致的皮肤屏障损伤被检测为VRE定植的其他危险因素。